Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
Cerone MA, Mills TC, Sharpe R, McBride D, MacDonald M, MacMahon S, Mugalaasi H, Rehal P, Rettino A, Roberts H, Ross M, White DE, Peden J, Rawlinson J, Ho SN, Hollingsworth S, Popat S, Middleton G, Johnson P, Swanton C; SMP2 consortium. Cerone MA, et al. Among authors: hollingsworth s. Br J Cancer. 2023 Jan;128(2):161-164. doi: 10.1038/s41416-022-02107-8. Epub 2023 Jan 4. Br J Cancer. 2023. PMID: 36599918 Free PMC article.
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
Cerone MA, Mills TC, Sharpe R, McBride D, MacDonald M, MacMahon S, Mugalaasi H, Rehal P, Rettino A, Roberts H, Ross M, White DE, Peden J, Rawlinson J, Ho SN, Hollingsworth S, Popat S, Middleton G, Johnson P, Swanton C; SMP2 consortium. Cerone MA, et al. Among authors: hollingsworth s. Br J Cancer. 2023 Jan;128(2):399. doi: 10.1038/s41416-023-02160-x. Br J Cancer. 2023. PMID: 36697967 Free PMC article. No abstract available.
Defining actionable mutations for oncology therapeutic development.
Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC. Carr TH, et al. Nat Rev Cancer. 2016 Apr 26;16(5):319-29. doi: 10.1038/nrc.2016.35. Nat Rev Cancer. 2016. PMID: 27112209 Review.
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, Farrington PM, Karmokar A, Willis SE, Cairns J, Nikkilä J, Beattie D, Lamont GM, Finlay MRV, Wilson J, Smith A, O'Connor LO, Ling S, Fawell SE, O'Connor MJ, Hollingsworth SJ, Dean E, Goldberg FW, Davies BR, Cadogan EB. Fok JHL, et al. Among authors: hollingsworth sj. Nat Commun. 2019 Nov 7;10(1):5065. doi: 10.1038/s41467-019-12836-9. Nat Commun. 2019. PMID: 31699977 Free PMC article.
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A, Cheung SYA, Irurzun-Arana I, Goldwin A, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ. Yap TA, et al. Among authors: hollingsworth sj. Clin Cancer Res. 2021 Oct 1;27(19):5213-5224. doi: 10.1158/1078-0432.CCR-21-1032. Clin Cancer Res. 2021. PMID: 34301752 Free PMC article. Clinical Trial.
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK. Lee J, et al. Among authors: hollingsworth sj. Cancer Discov. 2019 Oct;9(10):1388-1405. doi: 10.1158/2159-8290.CD-19-0442. Epub 2019 Jul 17. Cancer Discov. 2019. PMID: 31315834
144 results